On March 13, 2026, China’s National Medical Products Administration (NMPA) issued what is being described as the world’s first medical-device registration certificate for an invasive brain–computer interface, awarded to the Neuracle NEO system. The approval marks the official opening of what industry participants are calling the “first commercialization year” for invasive BCI technology. A field long subjected to the running joke that it is “always five years away” has now been given, through the combined action of the NMPA and the healthcare insurance authority, a pathway that can be paid for with a standard medical insurance card.
The Engineering Philosophy Behind the Neuracle NEO System
Neuracle was founded in 2011, drawing on biomedical engineering expertise from Tsinghua University and clinical resources from Huashan Hospital. Rather than adopting the aggressive cortical implantation approach associated with Neuralink — which requires opening the skull — the company pursued a semi-invasive, epidural route that places electrodes outside the dura mater. The procedure mills only a coin-sized groove in the skull, avoiding brain tissue entirely while still capturing signals of sufficient quality for clinical use.
The system’s technical centerpiece is its wireless power and communication architecture. The implanted unit carries no battery; instead, it draws power through near-field wireless transmission from an external unit that communicates through the scalp. The result is a design intended for permanent implantation without the need for subsequent surgery to replace a power source. The system pairs with a pneumatic glove in a closed-loop configuration: when a patient intends to grasp an object, the glove inflates and closes, providing direct physical and visual feedback.
Clinical trial data collected across 11 top-tier tertiary hospitals offer early evidence of the system’s efficacy. At six months post-surgery, follow-up of 32 patients with cervical spinal cord injury and complete loss of hand function showed grasping improvement across all participants. Some patients exhibited signs of neural remodeling and recovered partial neural function beyond what the device itself provides. In Jiangsu, the trial’s first subject was able to operate a mobile phone independently ten months after surgery. In Shanghai, a 61-year-old patient lifted a two-kilogram dumbbell with a bare hand eight months post-implantation.
The approach reflects a deliberate engineering calculus: rather than pushing for the deepest possible implantation, the system is optimized for the point at which signal quality and surgical risk reach an acceptable equilibrium.
The Regulatory Milestone: What This Registration Certificate Actually Means
If non-invasive BCI is a bicycle, invasive BCI has previously resembled a supersonic fighter jet in regulatory terms — the equivalent of asking a civil aviation authority to certify a military aircraft for commercial flight. Globally, Neuralink remains in the FDA’s breakthrough device designation corridor. China has now moved directly to formal Class III medical device registration.
The significance lies in a fundamental reorientation of regulatory logic. Prior to this approval, brain–computer interface products existed in a gray zone governed primarily by research ethics review processes. Companies could raise capital on the strength of a compelling narrative, but had no established clinical pathway, no adverse-event monitoring standard, and no valuation framework that a conventional financial model could accommodate. Bringing BCI under formal medical-device registration changes all of that: review standards, clinical pathways, and post-market surveillance now operate according to defined national criteria. Investors can apply a discounted cash flow model rather than counting pages in a business plan.
The specific data that completed the regulatory case was long-term follow-up from Jiangsu’s first implantation case: at 240 days post-surgery, signal decoding accuracy remained above 90% with no serious adverse events recorded. That result provided the evidentiary foundation for the NMPA’s determination that the long-term biocompatibility risk of subdural electrode placement is manageable. The certification also functions as a navigational reference for companies in the queue behind Neuracle — among them StairMed and BrainCo Tech — substantially reducing the uncertainty around device review methodology and accelerating the path to approval.
The Payment Milestone: How Medical Insurance Pricing Opens the Commercialization Ceiling
There is a well-worn observation in the medical device industry: the most sophisticated technology frequently fails not in the laboratory but in the reimbursement catalog. Had brain–computer interfaces remained dependent on a research-collaboration model — combining patient self-pay with company subsidies — the addressable market would have remained roughly comparable in scale to high-end dental care: technically impressive, but structurally niche.
In September 2025, Guangdong’s medical insurance authority moved first, announcing capped pricing standards for invasive BCI procedures. The implantation procedure is priced at RMB 6,600 (approximately USD 958.98, or approximately KRW 1,342,572) and the removal procedure at RMB 3,200 (approximately USD 464.96, or approximately KRW 650,944), with reimbursement processed through the diagnosis-related group payment system.
The reimbursement architecture is designed as a tiered pyramid. At the base, basic medical insurance covers hard-core functional reconstruction indications — high-level paraplegia and post-stroke hemiplegia — processed through a DRG green channel for disease-based payment. At the middle tier, commercial insurance is expected to target improvement-type indications including depression and early-stage Alzheimer’s intervention, referencing the special-drug catalog model established by Shenzhen’s Huiminbao program. At the top, out-of-pocket expenditure covers functional reconstruction beyond the scope of basic insurance — bilateral fine motor coordination training, customized neuro-rehabilitation programs — as well as long-term neural optimization services delivered through high-end rehabilitation centers.
The commercial model that emerges from this structure moves decisively away from a one-off transaction and toward recurring revenue: hardware implant, plus surgical implantation, plus annual maintenance covering signal calibration, plus ongoing software upgrades for algorithm optimization.
The Industry Positioning Battle Under the 15th Five-Year Plan
Shanghai currently leads China’s BCI industrialization effort, drawing on accumulated research from Fudan University, Shanghai Jiao Tong University, and the Chinese Academy of Sciences. The city has produced approximately 60 innovative companies in the sector — among them Neuracle, StairMed, BrainCo Tech, Shenfujianxing, Yansi Brain-inspired, Shuli, Siyi, Quanlan, Niantong, and others — spanning invasive, semi-invasive, and non-invasive technical routes. Three invasive products have already entered the national special review program for innovative medical devices.
Jiangsu Province is moving quickly in pursuit. The Jiangsu Province Action Plan for Innovative Development of the Brain–Computer Interface Industry sets out ambitions to cultivate two to three enterprises of domestic and international influence by 2030, build a closed loop across the full industrial chain, and establish what the plan describes as a “Neurotech Silicon Valley” in southern Jiangsu.
For the medical device manufacturing sector more broadly, the group with the most immediate cause for concern may be rehabilitation-department equipment vendors. When patients can direct a robotic arm through neural intent alone, conventional myoelectric prosthetics face the risk of obsolescence at a pace that could resemble the displacement of the pager. Initiating brain-control compatibility research and development is likely to become a near-term strategic imperative rather than a longer-term option.
Three Structural Challenges in Commercial Deployment
The commercial prospects for invasive BCI are substantive. Three significant constraints, however, deserve clear-eyed acknowledgment alongside the optimism.
The physician learning curve is steep. Neurosurgeons are expected to require twelve to eighteen months to achieve reliable proficiency in precise electrode implantation. In the near term, the procedure will be available at only a small number of institutions. Developing a surgical robot for electrode implantation — following a trajectory similar to Neuralink’s — is an important technical direction for addressing this bottleneck.
Data privacy and compliance costs represent a second structural challenge. A device capable of reading motor intent operates in proximity to information that could be characterized as recording subconscious preferences. Patients and regulators alike will ask whether neural data can be protected from unauthorized access or disclosure. Companies will need to invest in neural-data security architecture proactively rather than reactively.
Regional fragmentation in insurance coverage is the third constraint. Guangdong moved first, but other provinces are likely to observe developments before committing to equivalent frameworks. In the first three to five years of commercial deployment, the BCI market may in practice be concentrated within what are effectively medical special economic zones — the Greater Bay Area and the Yangtze River Delta.
Conclusion
The first device registration approval is not a conclusion; it is the point at which serious medical commercialization of invasive BCI begins. When a technology migrates from a compelling concept into a reimbursable medical product whose internal rate of return can be modeled with conventional financial tools, something structurally significant has occurred. The field may be approaching what could be called neurotech’s insulin moment: the point at which the technology ceases to be remarkable and begins to become indispensable.
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.